The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Open accessAbstract
Aptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic. Since the discovery of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like cancer, HIV, and macular degeneration. In the last two decades, many aptamers have been clinically developed as inhibitors for targets such as vascular endothelial growth factor (VEGF) and thrombin. The first aptamer based therapeutic was FDA approved in 2004 for the treatment of age-related macular degeneration and several other aptamers are currently being evaluated in clinical trials. With advances in targeted-therapy, imaging, and nanotechnology, aptamers are readily considered as potential targeting ligands because of their chemical synthesis and ease of modification for conjugation. Preclinical studies using aptamer-siRNA chimeras and aptamer targeted nanoparticle therapeutics have been very successful in mouse models of cancer and HIV. In summary aptamers are in several stages of development, from pre-clinical studies to clinical trials and even as FDA approved therapeutics. In this review, we will discuss the current state of aptamers in clinical trials as well as some promising aptamers in pre-clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 4×
“VEGF165 is a homodimeric protein of two 165 amino acid polypeptide chains and it is critical in blood vessel formation and in causing the increased permeability involved in vision loss associated with neovascular AMD [28].”
BackgroundInfluentialDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.
Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., & Springer, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3652 · Cited by 1,198
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Tenascin: An Extracellular Matrix Protein Prominent in Specialized Embryonic Tissues and Tumors
Erickson, H. P., & Bourdon, M. A. (1989) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.05.110189.000443 · Cited by 605
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Wright, G. L., Haley, C., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 591
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Lupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Self-citationInduction of tenascin in healing wounds
Mackie, E. J., Halfter, W., & Liverani, D. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.6.2757 · Cited by 555 · cited 1×
“It is associated with tissue remodeling processes such as angiogenesis, embryonic development, wound healing, and tumor growth [79-82].”
BackgroundMUC1, The Renaissance Molecule
Gendler, S. J. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1011379725811 · Cited by 552
Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513
RNA aptamers as reversible antagonists of coagulation factor IXa
Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512
The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
Soundararajan, S., Chen, W., Spicer, E. K., Courtenay-Luck, N., & Fernandes, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5723 · Cited by 512
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
Sullenger, B. A., Gallardo, H. F., Ungers, G. E., & Gilboa, E. (1990) · Cell · doi:10.1016/0092-8674(90)90455-n · Cited by 443
Ferreira, C. S. M., Matthews, C. S., & Missailidis, S. (2006) · Tumor Biology · doi:10.1159/000096085 · Cited by 407
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Inhibitory DNA Ligands to Platelet-Derived Growth Factor B-Chain
Green, L. S., Jellinek, D., Jenison, R., Östman, A., Heldin, C.-H., & Janjic, N. (1996) · Biochemistry · doi:10.1021/bi961544+ · Cited by 390
Tumor targeting by an aptamer.
Hicke, B. J., Stephens, A. W., Gould, T. A., Chang, Y.-F., Lynott, C. K., Heil, J., Borkowski, S., Hilger, C. S., Cook, G., Warren, S., et al. (2006) · PubMed · Cited by 384
Heath, J. R., & Davis, M. E. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.185523 · Cited by 354
Mechanisms Underlying Aberrant Glycosylation of MUC1 Mucin in Breast Cancer Cells
Brockhausen, I., Yang, J., Burchell, J., Whitehouse, C., & Taylor‐Papadimitriou, J. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.607_2.x · Cited by 346
Girling, A. C., Bártková, J., Burchell, J., Gendler, S. J., Gillett, C., & Taylor-Papadimitriou, J. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430620 · Cited by 330
Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein
Hicke, B. J., Marion, C., Chang, Y.-F., Gould, T., Lynott, C. K., Parma, D., Schmidt, P. G., & Warren, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104651200 · Cited by 324
Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer
Savla, R., Taratula, O., Garbuzenko, O., & Minko, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.015 · Cited by 314
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Shi, H., He, X., Wang, K., Wu, X., Ye, X., Guo, Q., Tan, W., Qing, Z., Yang, X., & Zhou, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016197108 · Cited by 301
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions
Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298
Hwang, D. W., Ko, H. Y., Lee, J. H., Kang, H., Ryu, S. H., Song, I. C., Lee, D. S., & Kim, S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069880 · Cited by 293
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Schmidt, K. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh862 · Cited by 287
Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., BouFakhreddine, S., Holohan, T. V., & Schaub, R. G. (2007) · Circulation · doi:10.1161/circulationaha.107.724864 · Cited by 286
Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., & Janjić, N. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90032-2 · Cited by 284
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention
Mamo, T., Moseman, E. A., Kolishetti, N., Salvador-Morales, C., Shi, J., Kuritzkes, D. R., Langer, R., Andrian, U. V., & Farokhzad, O. C. (2010) · Nanomedicine · doi:10.2217/nnm.10.1 · Cited by 255
Girvan, A. C., Teng, Y., Casson, L. K., Thomas, S. D., Jüliger, S., Ball, M. W., Klein, J. B., Pierce, W. M., Barve, S. S., & Bates, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0361 · Cited by 235
Inhibitors of Ocular Neovascularization: Promises and Potential Problems
van Wijngaarden, P., Coster, D. J., & Williams, K. A. (2005) · JAMA · doi:10.1001/jama.293.12.1509 · Cited by 228
Wheeler, L. A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z., Seung, E., Deruaz, M., Dudek, T., Einarsson, J. I., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45876 · Cited by 227
Koukoulis, G. K., Gould, V. E., Bhattacharyya, A., Gould, J. E., Howeedy, A. A., & Virtanen, I. (1991) · Human Pathology · doi:10.1016/0046-8177(91)90285-w · Cited by 222
Potent 2'-Amino-2'-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor
Jellinek, D., Green, L. S., Bell, C., Lynott, C. K., Gill, N., Vargeese, C., Kirschenheuter, G., McGee, D. P. C., & Abesinghe, P. (1995) · Biochemistry · doi:10.1021/bi00036a009 · Cited by 215
Mirror-design of L-oligonucleotide ligands binding to L-arginine
Nolte, A., Klußmann, S., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996) · Nature Biotechnology · doi:10.1038/nbt0996-1116 · Cited by 206
Aptamer-Facilitated Biomarker Discovery (AptaBiD)
Berezovski, M. V., Lechmann, M., Musheev, M. U., Mak, T. W., & Krylov, S. N. (2008) · Journal of the American Chemical Society · doi:10.1021/ja801951p · Cited by 198
Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus Nephritis in MRL-(Fas)lpr Mice
Kulkarni, O., Pawar, R. D., Purschke, W., Eulberg, D., Selve, N., Buchner, K., Ninichuk, V., Segerer, S., Vielhauer, V., Klussmann, S., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121348 · Cited by 187
Modified RNA sequence pools for in vitro selection
Lin, Y., Qiu, Q., Gill, S. C., & Jayasena, S. D. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.24.5229 · Cited by 182
MRI Detection of Thrombin with Aptamer Functionalized Superparamagnetic Iron Oxide Nanoparticles
Yigit, M. V., Mazumdar, D., & Lu, Y. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7003928 · Cited by 177
Sultan, M. B., Zhou, D., Loftus, J., Dombi, T., & Ice, K. S. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.045 · Cited by 172
Escort aptamers: a delivery service for diagnosis and therapy
Hicke, B. J., & Stephens, A. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11324 · Cited by 169
Khati, M., Schüman, M., Ibrahim, J., Sattentau, Q., Gordon, S., & James, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12692-12698.2003 · Cited by 169
Alterations of O-glycan biosynthesis in human colon cancer tissues
Yang, J.-M., Byrd, J. C., Siddiki, B. B., Chung, Y.-S., Okuno, M., Sowa, M., Kim, Y. S., Matta, K. L., & Brockhausen, I. (1994) · Glycobiology · doi:10.1093/glycob/4.6.873 · Cited by 169
Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J. (2009) · Diabetologia · doi:10.1007/s00125-009-1493-6 · Cited by 166
In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase
Charlton, J., Sennello, J., & Smith, D. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90114-9 · Cited by 163
Duerschmied, D., Merhi, Y., Tanguay, J., Hutabarat, R. M., GILBERT, J., Wagner, D. D., Schaub, R. G., Diener, J. L., & Lagassé, H. A. D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03459.x · Cited by 156
Tenascin expression in astrocytomas correlates with angiogenesis.
Zagzag, D., Friedlander, D. R., Miller, D. C., Dosik, J., Cangiarella, J. F., Kostianovsky, M., Cohen, H. W., Grumet, M., & GRECO, M. A. (1995) · PubMed · Cited by 156
Derivation of RNA aptamer inhibitors of human complement C5
Biesecker, G., Dihel, L., Enney, K., & Bendele, R. A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00020-x · Cited by 152
Ninichuk, V., Clauß, S., Kulkarni, O. P., Schmid, H., Segerer, S., Radomska, E., Eulberg, D., Buchner, K., Selve, N., Klußmann, S., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070601 · Cited by 146
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts
Ni, X., Zhang, Y., Ribas, J., Chowdhury, W. H., Castanares, M. A., Zhang, Z., Laiho, M., DeWeese, T. L., & Lupold, S. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45109 · Cited by 143
Self-citationReagan‐Shaw, S., & Ahmad, N. (2005) · The FASEB Journal · doi:10.1096/fj.04-2910fje · Cited by 138
Technology Insight: monoclonal antibody imaging of prostate cancer
Bander, N. H. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0452 · Cited by 130
Chan, M. Y., Cohen, M. G., Dyke, C. K., Myles, S. K., Aberle, L. G., Lin, M. J., Walder, J. S., Steinhubl, S. R., Gilchrist, I. C., Kleiman, N. S., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.745687 · Cited by 130
Selection and Characterization of an RNA Decoy for Transcription Factor NF-κB
Lebruska, L. L., & Maher, L. J. (1999) · Biochemistry · doi:10.1021/bi982515x · Cited by 117
Post-SELEX combinatorial optimization of aptamers
Eaton, B. E., Gold, L., Hicke, B. J., Janjié, N., Jucker, F. M., Sebesta, D. P., Tarasow, T. M., Willis, M. C., & Zichi, D. A. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(97)00044-8 · Cited by 115
Combination therapy for the treatment of ocular neovascularization
Bradley, J. M. B., Ju, M., & Robinson, G. S. (2007) · Angiogenesis · doi:10.1007/s10456-007-9069-x · Cited by 115
Mann, A. P., Somasunderam, A., Nieves-Alicea, R., Li, X., Hu, A. H., Sood, A. K., Mauro Ferrari, B., Gorenstein, D. G., & Tanaka, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013050 · Cited by 106
Watson, S. R., Chang, Y.-F., O'Connell, D., WEIGAND, L., Ringquist, S., & Parma, D. H. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.63 · Cited by 79
Lin, Y.-L. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.17.3407 · Cited by 67
2´-Deoxy Purine, 2´-O-Methyl Pyrimidine (dRmY) Aptamers as Candidate Therapeutics
Burmeister, P. E., Wang, C., Killough, J. R., Lewis, S. D., Horwitz, L. R., Ferguson, A., Thompson, K. M., Pendergrast, P. S., McCauley, T. G., Kurz, M., et al. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.337 · Cited by 67
Neutrophil Elastase and Cathepsin G: Structure, Function, and Biological Control
Wątorek, W., FARLEY, D. L., Salvesen, G. S., & Travis, J. C. (1988) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-1057-0_3 · Cited by 43
Povsic, T. J., Cohen, M. G., Mehran, R., Buller, C. E. H., Bode, C., Cornel, J. H., Kasprzak, J. D., Montalescot, G., Joseph, D., Wargin, W. A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.10.022 · Cited by 37
Antisense Treatment in Human Prostate Cancer and Melanoma
Cresce, C. D., & Koropatnick, J. D. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791859452 · Cited by 33
Cosmi, B. (2009) · PubMed · Cited by 31
Cited by
Nanomaterials enhanced surface plasmon resonance for biological and chemical sensing applications
Zeng, S., Baillargeat, D., Ho, H.-P., & Yong, K.-T. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60479a · Cited by 1,230
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Metadata
- Authors
- Ni, X., Castanares, M., Mukherjee, A., & Lupold, S. E.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-09-01
- Volume
- 18
- Issue
- 27
- Pages
- 4206-4214
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2100181290
- Cited by
- 349
- References
- 77
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.